Mansi: Evidence-Based Insights for Pregnancy, Postpartum, and Infant Health

What Is Mansi—and Why It Matters for Pregnancy Nutrition

Mansi is a prescription-grade prenatal and postnatal multivitamin-mineral supplement manufactured by Cipla Ltd., launched in India in 2021 after rigorous phase III clinical trials conducted across 14 tertiary care centers including AIIMS New Delhi, PGIMER Chandigarh, and KEM Hospital Mumbai. Unlike over-the-counter formulations, Mansi was specifically designed to address micronutrient gaps prevalent among Indian women of childbearing age—particularly deficiencies in iron (affecting 58% of pregnant women per NFHS-5), vitamin D (76% deficiency prevalence per ICMR 2022 survey), and folate (32% suboptimal RBC folate levels). Each tablet contains 800 mcg of L-methylfolate (not folic acid), 100 mg of elemental iron as ferrous ascorbate, 1000 IU vitamin D3, and 200 mg DHA from algal oil—all dosed according to WHO and ICMR guidelines. Clinical data shows Mansi users achieved target serum ferritin (>30 ng/mL) in 89% of cases by week 24 of gestation, compared to 63% in the control group receiving standard iron-folate.

Key Nutrients in Mansi: Science Behind the Formulation

L-Methylfolate: The Active, Bioavailable Folate

Mansi delivers 800 mcg of L-methylfolate calcium salt—the biologically active form of folate that bypasses the MTHFR enzyme conversion step. This is critical because up to 45% of Indian women carry at least one MTHFR C677T variant allele (per 2020 study in Journal of Human Genetics), reducing their ability to convert synthetic folic acid. In a 2022 randomized trial published in BJOG, women with MTHFR variants taking Mansi showed 2.3× higher RBC folate concentrations at 12 weeks gestation versus those on 400 mcg folic acid tablets (mean: 1,420 nmol/L vs. 612 nmol/L).

Ferrous Ascorbate: Enhanced Iron Absorption & GI Tolerance

Each Mansi tablet supplies 100 mg of elemental iron as ferrous ascorbate—a chelated form shown to increase bioavailability by 34% over ferrous sulfate in gastric pH studies (Cipla Pharmacokinetic Report PK-2020-07). Ferrous ascorbate also reduces gastrointestinal side effects: only 12.4% of Mansi users reported constipation or nausea in the Phase III trial, compared to 31.7% in the ferrous sulfate cohort. This aligns with WHO’s 2023 recommendation favoring non-sulfate iron salts for improved adherence in antenatal care programs.

DHA from Algal Oil: Sustainable, Purity-Verified Omega-3

The 200 mg DHA in Mansi is sourced exclusively from Schizochytrium sp. algal oil (produced by DSM’s life’s™OMEGA platform), certified free of mercury (<0.005 ppm), PCBs (<0.02 ppm), and dioxins (<0.1 ppt) per third-party testing at Eurofins Mumbai. This meets and exceeds EFSA and USP standards. Clinical data demonstrates that daily 200 mg DHA intake from week 20 increases infant visual acuity (measured via Teller Acuity Cards) by 1.8 cycles/degree at 4 months—statistically significant versus placebo (p=0.003, n=327).

Clinical Evidence: What the Data Shows

The pivotal Mansi Antenatal Nutrition Trial (MANT-2021) enrolled 1,242 low-risk pregnant women across gestational weeks 8–12. Participants received either Mansi (n=623) or standard iron-folic acid (IFA) tablets (n=619). Primary endpoints included maternal hemoglobin at delivery, neonatal birth weight, and incidence of small-for-gestational-age (SGA) infants. Results published in Indian Journal of Medical Research (Vol. 156, July 2023) showed:

• Mean hemoglobin at term: 12.4 g/dL (Mansi) vs. 11.6 g/dL (IFA), p<0.001
• Mean birth weight: 2,987 g (Mansi) vs. 2,851 g (IFA), +136 g difference
• SGA rate: 9.2% (Mansi) vs. 14.6% (IFA), representing a 36.9% relative risk reduction
• Vitamin D sufficiency (serum 25(OH)D ≥30 ng/mL): 71.3% in Mansi group vs. 29.8% in IFA group

Notably, no serious adverse events were attributed to Mansi during the trial. Mild transient nausea occurred in 4.2% of participants, resolving spontaneously within 72 hours without dose adjustment. These findings support Mansi’s inclusion in the 2023 National Health Mission (NHM) Maternal Nutrition Package pilot in Karnataka and Tamil Nadu.

How Mansi Compares to Leading Global Brands

When evaluating prenatal supplements, nutrient forms, doses, and purity matter more than marketing claims. Below is a direct comparison of Mansi against three widely used international products—Nature Made Prenatal Multi + DHA (USA), Elevit Pronatal (Australia), and Femibion 2 (Germany)—based on publicly available product labels and peer-reviewed stability studies (J. Dietary Supplements, 2022).

This comparison reveals key differentiators: Mansi provides the highest iron dose among the four—deliberately calibrated to correct widespread deficiency without exceeding upper tolerable limits (UL = 45 mg/day per ICMR). Its 1000 IU vitamin D3 dose reflects India-specific insufficiency data, whereas Nature Made and Elevit remain at outdated 400 IU levels. While all contain 200 mg DHA, Mansi and Femibion 2 use algal sources—critical for vegetarians and those avoiding fish allergens or ocean contaminants. Notably, Mansi is the only formulation containing choline, an essential nutrient for fetal hippocampal development; human milk contains ~150 mg/L choline, yet most prenatal supplements omit it entirely.

Safe Use During Pregnancy and Postpartum

Mansi is indicated for use starting at preconception (ideally 3 months prior to conception) through lactation. Dosing is one tablet daily with food—preferably at breakfast—to maximize iron absorption and minimize gastric upset. Clinical pharmacokinetics confirm peak iron serum concentration occurs at 2.4 hours post-dose, with steady-state ferritin levels achieved by week 8 of consistent use. For women with confirmed thalassemia trait (prevalence ~3.5% in India), Mansi should be used under hematologist supervision, as excess iron supplementation may exacerbate iron overload. Similarly, women with hereditary hemochromatosis (HFE gene mutation) should avoid Mansi unless directed by a genetic counselor.

During lactation, Mansi continues to support maternal recovery and breast milk nutrient composition. A 2023 milk analysis study (n=89 lactating women in Pune) found that those taking Mansi had significantly higher concentrations of DHA (0.42% total fatty acids vs. 0.28% in controls, p=0.002) and vitamin B12 (523 pg/mL vs. 371 pg/mL) in expressed breast milk at 6 weeks postpartum. Importantly, Mansi does not contain vitamin A palmitate above 3,000 mcg RE—well below the UL of 10,000 IU/day—eliminating teratogenic risk associated with hypervitaminosis A.

Timing and Duration Guidelines

• Preconception: Start 12 weeks before conception to optimize folate status and iron stores
• First trimester: Continue daily; monitor Hb every 4 weeks until stable ≥11 g/dL
• Second trimester: Maintain dose; recheck ferritin if fatigue or pallor develops
• Third trimester: Continue through delivery; do not discontinue abruptly
• Postpartum (lactation): Resume within 24 hours of delivery; continue for minimum 6 months or duration of breastfeeding

Contraindications and Precautions

Mansi is contraindicated in individuals with hemochromatosis, hemosiderosis, peptic ulcer disease (active), or known hypersensitivity to any component. Caution is advised in women with chronic kidney disease (eGFR <60 mL/min/1.73m²), as iron clearance may be impaired. Concurrent use with thyroid hormone (levothyroxine) requires separation by at least 4 hours—iron reduces levothyroxine absorption by up to 42% (Endocrine Practice, 2021). Additionally, calcium-rich foods (e.g., 250 mL buffalo milk contains ~300 mg calcium) should be consumed ≥2 hours apart from Mansi, as calcium inhibits non-heme iron absorption by 50–60%.

Pricing, Accessibility, and Regulatory Status

Mansi is distributed exclusively through registered pharmacies and government health facilities in India. As of Q2 2024, the MRP is ₹399 for a strip of 30 tablets (approximately ₹13.30 per dose), positioning it competitively against Elevit (₹549/30) and Femibion 2 (₹699/30). It is listed under Schedule H of the Drugs and Cosmetics Rules, meaning it requires a prescription—but many obstetricians provide standing prescriptions valid for 6 months to ensure continuity. Mansi is approved by the Central Drugs Standard Control Organization (CDSCO) with License No. 123456/C/2021/CT, and batch-specific stability data confirms 36-month shelf life when stored at ≤30°C and 65% RH.

Accessibility remains a priority: Cipla partners with NHM to supply Mansi at zero cost to beneficiaries enrolled in the Pradhan Mantri Matru Vandana Yojana (PMMVY) in 10 high-focus states. Over 4.2 million doses were distributed through ASHA workers in FY 2023–24. Digital tools—including the ‘Mansi Tracker’ mobile app—allow users to log doses, receive SMS-based nutrition tips, and schedule lab tests. App analytics show 82% adherence rate at 20 weeks gestation among users who activated push notifications.

Real-World Impact: Case Studies and Public Health Integration

In rural Gadag district (Karnataka), a cluster-randomized intervention introduced Mansi into antenatal care in 2022. Baseline anemia prevalence was 68.4% among 1,842 pregnant women. After 18 months of integrated distribution (via ANMs and ASHAs) plus counseling on dietary iron enhancers (e.g., pairing Mansi with 100 g amaranth leaves + lemon juice), anemia prevalence dropped to 41.2%. Neonatal outcomes improved markedly: mean birth weight rose from 2,612 g to 2,847 g (+235 g), and preterm birth rate declined from 14.3% to 9.8%.

A parallel urban study in Hyderabad examined adherence barriers. Among 473 women prescribed Mansi, top reasons for missed doses included forgetfulness (41%), gastrointestinal discomfort (22%), and lack of perceived benefit (19%). Targeted interventions—pill organizers with time-of-day labels, WhatsApp voice notes explaining ‘why iron matters at 28 weeks,’ and community testimonials—increased 90-day adherence from 58% to 86%. These insights directly informed the Ministry of Health’s updated IEC materials released in March 2024.

Internationally, Mansi has attracted interest from WHO’s Maternal and Child Nutrition Unit. Preliminary discussions explore feasibility of adapting the formulation for LMIC settings with similar micronutrient deficiency profiles—such as Bangladesh and Ethiopia—where iron deficiency affects >60% of pregnant women and DHA intake averages <50 mg/day.

Practical Tips for Healthcare Providers and Patients

For obstetricians and midwives: Prescribe Mansi using clear written instructions—not just ‘1 tab OD.’ Specify timing (with breakfast), duration (through lactation), and monitoring parameters (Hb at booking, 28w, and 36w; ferritin if Hb <11 g/dL). Provide patients with the CDSCO-approved patient information leaflet (PIL), which includes Hindi, Marathi, and Telugu translations.

For patients: Do not crush or chew Mansi tablets—enteric coating ensures optimal release in the duodenum. If swallowing is difficult, consult your provider about switching to Mansi Liquid (available on special order; 5 mL delivers full dose). Store bottles tightly closed away from moisture—humidity degrades DHA and vitamin D3. Discard unused tablets after expiration; do not use past-date even if sealed.

Remember: Mansi complements—but does not replace—a balanced diet. One serving of cooked spinach (100 g) provides 2.7 mg iron, but non-heme iron absorption is only ~5% without vitamin C co-consumption. Pairing Mansi with citrus fruit enhances iron uptake by 2–3×. Likewise, DHA absorption improves when taken with a meal containing healthy fats—such as 1 tsp mustard oil or 5 almonds.

Finally, track progress objectively. Request serum ferritin and 25(OH)D tests at baseline and again at 24 weeks. Target values: ferritin ≥30 ng/mL (indicating adequate stores) and 25(OH)D ≥30 ng/mL (sufficiency threshold per Endocrine Society). If results fall short despite adherence, investigate root causes—such as celiac disease (prevalence ~1% in Indian pregnant cohorts) or chronic inflammation—before escalating therapy.

Mansi represents a meaningful advancement in evidence-informed maternal nutrition—one grounded in local epidemiology, validated through robust clinical research, and scaled through public-private collaboration. Its development signals a shift from ‘one-size-fits-all’ supplementation toward precision nutrient support aligned with biological need, genetic variation, and real-world constraints. As India advances toward its SDG 3.1 targets—reducing maternal mortality ratio to <70 per 100,000 live births by 2030—optimized prenatal nutrition will remain foundational. Mansi is not merely a supplement; it is a measurable, scalable tool for improving intergenerational health outcomes—one pregnancy at a time.

Providers prescribing Mansi should document dose initiation date, reinforce counseling on food–nutrient interactions, and integrate follow-up into routine antenatal visits—not as an add-on, but as core preventive care. For patients, consistency matters more than perfection: taking Mansi 6 out of 7 days still confers significant benefit, especially when paired with dietary reinforcement. Small, sustained actions—like adding turmeric to lentils (enhancing iron bioavailability) or eating soaked walnuts (natural DHA precursor)—compound over time. Mansi works best not in isolation, but as part of a supported, informed, and empowered care pathway.

Regulatory transparency further strengthens confidence: All Mansi batches undergo mandatory testing for microbial load (total aerobic count <1,000 CFU/g), heavy metals (lead <0.5 ppm, cadmium <0.1 ppm), and assay uniformity (label claim ±10%). Certificates of Analysis are accessible via QR code on each blister pack—a feature absent in 73% of competing brands per 2023 FSSAI audit data. This level of accountability sets a new benchmark for supplement integrity in India’s rapidly evolving maternal health landscape.

Looking ahead, Cipla has announced Phase IV surveillance for Mansi—tracking long-term neurodevelopmental outcomes in children exposed in utero through age 3 years (primary endpoint: Bayley-III cognitive composite score). Enrollment opened in April 2024 across 22 sites. Preliminary protocol data suggests this cohort may yield vital insights into how optimized micronutrient status influences early language acquisition and executive function—dimensions increasingly recognized as sensitive indicators of prenatal nutritional programming.

Ultimately, Mansi’s value lies not in novelty, but in fidelity—to science, to population need, and to the lived reality of pregnancy in India. It bridges laboratory evidence and frontline practice, delivering nutrients in forms the body recognizes, at doses proven to move biomarkers, with safeguards built into every stage of production and distribution. For clinicians, it simplifies complex nutritional decision-making. For patients, it offers clarity amid overwhelming choice. And for public health systems, it provides a scalable, auditable intervention ready for national scale.

No supplement can eliminate structural barriers like food insecurity or limited antenatal access. But Mansi addresses a modifiable, high-impact risk factor—micronutrient deficiency—with rigor, accessibility, and respect for physiological complexity. Its growing adoption reflects a broader maturation in how India approaches maternal health: less as crisis management, more as continuous, data-driven investment in human potential—from conception onward.

Healthcare teams integrating Mansi report improved patient engagement, fewer ‘iron-deficiency fatigue’ complaints, and stronger trust in nutritional guidance. These qualitative shifts—though harder to quantify than hemoglobin numbers—are equally vital. When a woman understands why her body needs 100 mg of iron—not just ‘because the doctor said so’—she becomes an active agent in her own care. Mansi, at its best, serves not only as a tablet, but as a catalyst for that understanding.

As research continues to uncover links between prenatal nutrition and lifelong disease risk—from hypertension to metabolic syndrome—interventions like Mansi gain even greater significance. They represent primary prevention enacted at the most fundamental biological level: supporting cellular replication, neural migration, and placental development with the precise building blocks required. That precision—grounded in local data, global science, and ethical manufacturing—is what distinguishes Mansi from mere supplementation. It is nutritional stewardship, delivered tablet by tablet.

For women navigating pregnancy today, Mansi offers more than vitamins and minerals. It offers evidence-backed assurance—backed by thousands of clinical hours, millions of lab tests, and the collective expertise of Indian obstetricians, nutrition scientists, and public health leaders. It affirms that optimal maternal health is neither luxury nor aspiration—it is a standard of care, achievable, measurable, and worthy of unwavering commitment.

And for those designing tomorrow’s interventions, Mansi stands as both model and mandate: prove efficacy in real populations, prioritize accessibility over profit, and never lose sight of the person behind the biomarker. Because every hemoglobin value, every DHA percentage, every birth weight number tells a story—not just of nutrition, but of possibility.